The effects of amlodipine and S(-)-amlodipine on vascular endothelial function in patients with hypertension

American Journal of Hypertension

Volumn 27, Issue 1, 2014, Pages 27-31

  Si, Daoyuan ^a   He, Yuquan ^a   Yang, Chunyan ^a   Ni, Lujia ^a   Li, Bing ^a   Ding, Mei ^a   Yang, Ping ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Amlodipine; Blood pressure; Doppler ultrasonography; Endothelial function; Hypertension; Phosphorylation; S( ) amlodipine

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; AMLODIPINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCERYL TRINITRATE; NITRIC OXIDE; PROTEIN KINASE C INHIBITOR; SERINE; THREONINE;

ADULT; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; ESSENTIAL HYPERTENSION; FEMALE; FLUSHING; HEART RATE; HUMAN; HUMAN CELL; HYPERTENSION; LEG EDEMA; MALE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

AMLODIPINE; BLOOD PRESSURE; DOPPLER ULTRASONOGRAPHY; ENDOTHELIAL FUNCTION; HYPERTENSION; PHOSPHORYLATION; S(-)-AMLODIPINE.;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CELLS, CULTURED; CHINA; CROSS-OVER STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; VASODILATION; VASODILATOR AGENTS;

EID: 84890501785     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpt138     Document Type: Article

References (15)

1. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M; CAFÉ Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113:1213-1225.
2. On YK, Kim CH, Oh BH, Lee MM, Park YB. Effects of angiotensin converting enzyme inhibitor and calcium antagonist on endothelial function in patients with essential hypertension. Hypertens Res 2002; 25:365-371.
3. Arrowsmith JE, Campbell SF, Cross PE, Stubbs JK, Burges RA, Gardiner DG, blackburn KJ. Long-Acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents. J Med Chem 1986; 29:1696-1702.
4. Zhang XP, Loke KE, Mital S, Chahwala S, Hintze TH. Paradoxical release of nitric oxide by an L-Type calcium channel antagonist, the R+ enantiomer of amlodipine. J Cardiovasc Pharmacol 2002; 39:208-214.
5. Zou J, Li Y, Fan HQ, Wang JG. Effects of dihydropyridine calcium channel blockers on oxidized low-density lipoprotein induced proliferation and oxidative stress of vascular smooth muscle cells. BMC Res Notes 2012; 5:168.
6. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340:1111-1115.
7. Kim BH, Kim JR, Kim MG, Kim KP, Lee BY, Jang IJ, Shin SG, Yu KS. Pharmacodynamic (hemodynamic) and pharmacokinetic comparisons of S-Amlodipine gentisate and racemate amlodipine besylate in healthy Korean male volunteers: two double-blind, randomized, two-period, two-Treatment, two-sequence, double-dummy, single-dose crossover studies. Clin Ther 2010; 32:193-205.
8. Oh GC, Lee HY, Kang HJ, Zo JH, Choi DJ, Oh BH. Quantification of pedal edema during treatment with S(-)-Amlodipine nicotinate versus amlodipine besylate in female Korean patients with mild to moderate hypertension: a 12-week, multicenter, randomized, double-blind, active-controlled, phase IV clinical trial. Clin Ther 2012; 34:1940-1947.
9. Sierkova VK, Kuz'minova NV, Alshantti IS. Comparative estimation of efficiency and safety of racemic amlodipine and its S-enantiomer in hypertensive patients. Lik Sprava 2009; (3-4):39-44.
10. Thacker HP. S-Amlodipine -The 2007 clinical review. J Indian Med Assoc 2007; 105:180-182, 184, 186.
11. Berkels R, Taubert D, Bartels H, Breitenbach T, Klaus W, Roesen R. Amlodipine increases endothelial nitric oxide by dual mechanisms. Pharmacology 2004; 70:39-45.
12. Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998; 97:576-580.
13. Lenasi H, Kohlstedt K, Fichtlscherer B, Mulsch A, Busse R, Fleming I. Amlodipine activates the endothelial nitric oxide synthase by altering phosphorylation on Ser1177 and Thr495. Cardiovasc Res 2003; 59:844-853.
14. Batova S, DeWever J, Godfraind T, Balligand JL, Dessy C, Feron O. The calcium channel blocker amlodipine promotes the unclamping of eNOS from caveolin in endothelial cells. Cardiovasc Res 2006; 71:478-485.
15. Higashi Y. [Mechanisms of impairment of endothelial cell]. Nihon Rinsho 2012; 70:1519-1523.